Renovorx increases u.s. production of renovocath® devices to meet growing demand from oncology community

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath, a novel, fda-cleared drug-delivery device, today announced that it is increasing production of its fda-cleared renovocath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists.
RNXT Ratings Summary
RNXT Quant Ranking